In-vivo Partial Cellular Reprogramming
Delivery mechanisms, epigenetic-clock effects in models, dedifferentiation risk, and translational bottlenecks.
Experimental & Translational Approaches
This section covers experimental biomedical approaches that aim to modify mechanisms linked to ageing biology, such as epigenetic state, immune function, extracellular matrix damage, mitochondrial dysfunction, and stem-cell signalling. It is a research map, not a recommendation guide: it focuses on what has been studied, what the evidence shows, and where translation remains uncertain.
Immune Rejuvenation
Research on immunosenescence, thymic involution, inflammaging, and engineered immune-cell approaches.
Engineered Immune Cells for Senescent Cell Clearance
uPAR CAR T-cell evidence, immune surveillance, target selection, safety, and translational limits.
In-Vivo Cell Engineering for Regenerative Medicine
Direct lineage reprogramming, transient immune-cell programming, delivery constraints, safety, and the limits of current regenerative evidence.
Synthetic Biology Approaches to Ageing Interventions
Synthetic gene circuits, engineered cells, cross-species enzymes, biological control systems, and the limits of current preclinical evidence.
Gene Therapies for Ageing
Experimental targets such as follistatin, telomerase, and Klotho, with attention to vector limits and human translation.
Telomerase-Based Therapies: Potential and Cancer Risk
Telomere maintenance, preclinical therapeutic evidence, delivery questions, and the risks associated with cellular immortalization and cancer.
CRISPR Base and Prime Editing in Ageing Research
Programmable sequence correction, progeria-model evidence, age-related disease variants, delivery constraints, and safety limits.
RNA Therapeutics for Ageing Biology
Antisense oligonucleotides, siRNA, mRNA, microRNA, RNA editing, delivery constraints, and the limits of current ageing evidence.
Targeted Delivery Systems
AAV tropism, lipid nanoparticles, extracellular vesicles, biodistribution, redosing, and immune-response limits.
Engineered Extracellular Vesicles for Regenerative Therapy
Vesicle engineering, therapeutic cargo delivery, regenerative applications, manufacturing constraints, and current evidence limits.
Epigenome Editing for Age-Related Dysfunction
Targeted control of gene regulation without changing DNA sequence, including delivery, durability, off-target effects, and translational uncertainty.
Heterochronic Parabiosis and TPE
Parabiosis findings, the addition-versus-dilution debate, and what plasma-exchange studies do and do not show.
Stem Cell Therapies and Exosomes
Whole-cell approaches, mesenchymal stem-cell evidence, extracellular vesicles, and standardization challenges.
Organoid Transplantation and Tissue Replacement
Organoid-derived tissue repair, vascularization and integration challenges, immune compatibility, safety, and the state of translational evidence.
Bioengineered Organs and 3D Bioprinting
Scaffolds, bioprinting, organ replacement strategies, vascularization, functional maturation, and barriers to treating age-related organ failure.
ECM Rejuvenation and Crosslink Breakers
The role of glucosepane and advanced glycation end-products in tissue stiffening, and experimental attempts to cleave crosslinks.
Mitochondrial Transfer and Allotopic Expression
Allotopic-expression concepts, mitochondrial transfer research, and the limits of current evidence.
Autophagy and Lysosomal Enhancement
Cellular clearance mechanisms, lysosomal regulation, model-organism evidence, measurement challenges, and translational limits.
Targeted Protein Degradation for Age-Related Disease
PROTACs, lysosomal degradation platforms, disease-specific preclinical evidence, delivery constraints, and safety limits.